総資産利益率 (ROA)
2005年以降
計算
Bristol-Myers Squibb Co.、 ROA、長期トレンド計算
| ROA | = | 100 | × | BMSに帰属する当期純利益(損失)1 | ÷ | 総資産1 | |
|---|---|---|---|---|---|---|---|
| 2024/12/31 | -9.66% | = | 100 | × | (8,948) | ÷ | 92,603) |
| 2023/12/31 | 8.43% | = | 100 | × | 8,025) | ÷ | 95,159) |
| 2022/12/31 | 6.53% | = | 100 | × | 6,327) | ÷ | 96,820) |
| 2021/12/31 | 6.40% | = | 100 | × | 6,994) | ÷ | 109,314) |
| 2020/12/31 | -7.61% | = | 100 | × | (9,015) | ÷ | 118,481) |
| 2019/12/31 | 2.65% | = | 100 | × | 3,439) | ÷ | 129,944) |
| 2018/12/31 | 14.06% | = | 100 | × | 4,920) | ÷ | 34,986) |
| 2017/12/31 | 3.00% | = | 100 | × | 1,007) | ÷ | 33,551) |
| 2016/12/31 | 13.22% | = | 100 | × | 4,457) | ÷ | 33,707) |
| 2015/12/31 | 4.93% | = | 100 | × | 1,565) | ÷ | 31,748) |
| 2014/12/31 | 5.94% | = | 100 | × | 2,004) | ÷ | 33,749) |
| 2013/12/31 | 6.64% | = | 100 | × | 2,563) | ÷ | 38,592) |
| 2012/12/31 | 5.46% | = | 100 | × | 1,960) | ÷ | 35,897) |
| 2011/12/31 | 11.25% | = | 100 | × | 3,709) | ÷ | 32,970) |
| 2010/12/31 | 9.98% | = | 100 | × | 3,102) | ÷ | 31,076) |
| 2009/12/31 | 34.22% | = | 100 | × | 10,612) | ÷ | 31,008) |
| 2008/12/31 | 17.76% | = | 100 | × | 5,247) | ÷ | 29,552) |
| 2007/12/31 | 8.27% | = | 100 | × | 2,165) | ÷ | 26,172) |
| 2006/12/31 | 6.20% | = | 100 | × | 1,585) | ÷ | 25,575) |
| 2005/12/31 | 10.66% | = | 100 | × | 3,000) | ÷ | 28,138) |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
1 百万米ドル
競合他社との比較
Bristol-Myers Squibb Co.、 ROA、長期トレンド、競合他社との比較
| Bristol-Myers Squibb Co. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024/12/31 | -9.66% | 3.17% | 4.45% | 5.03% | 13.45% | 0.81% | 7.81% | 14.62% | 3.76% | 11.69% | 6.51% | -2.38% |
| 2023/12/31 | 8.43% | 3.61% | 6.91% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 6.07% | 15.92% |
| 2022/12/31 | 6.53% | 8.53% | 10.06% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 7.15% | 18.30% |
| 2021/12/31 | 6.40% | 7.88% | 9.63% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 8.12% | 17.44% |
| 2020/12/31 | -7.61% | 3.07% | 11.54% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 9.23% | 23.07% |
| 2019/12/31 | 2.65% | 8.84% | 13.13% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 6.33% | 14.15% |
| 2018/12/31 | 14.06% | 9.58% | 12.64% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% | 33.57% |
| 2017/12/31 | 3.00% | 7.50% | 2.48% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 3.93% | 7.43% |
| 2016/12/31 | 13.22% | 9.01% | 9.95% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | 4.40% | -3.87% |
| 2015/12/31 | 4.93% | 9.70% | 9.69% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | 4.83% | -22.26% |
| 2014/12/31 | 5.94% | 6.44% | 7.47% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | 4.42% | -31.63% |
| 2013/12/31 | 6.64% | 14.14% | 7.68% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | 4.00% | -19.19% |
| 2012/12/31 | 5.46% | 19.53% | 8.00% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | 4.29% | -3.88% |
| 2011/12/31 | 11.25% | — | 7.54% | 7.25% | 12.92% | 16.20% | 8.51% | 5.97% | 5.32% | -16.75% | 4.96% | 1.34% |
| 2010/12/31 | 9.98% | — | 10.64% | 8.07% | 16.35% | 25.03% | 12.96% | 0.81% | 4.23% | -9.59% | 4.85% | -43.74% |
| 2009/12/31 | 34.22% | — | 11.62% | 5.88% | 15.76% | 27.18% | 12.95% | 11.51% | 4.05% | -9.15% | 3.93% | -32.84% |
| 2008/12/31 | 17.76% | — | 11.51% | 7.53% | -7.09% | 28.65% | 15.25% | 16.54% | 7.29% | -12.34% | 4.71% | -46.90% |
| 2007/12/31 | 8.27% | — | 9.14% | 7.84% | 11.02% | 27.68% | 13.06% | 6.77% | 7.07% | -11.28% | 3.59% | -65.05% |
| 2006/12/31 | 6.20% | — | 8.73% | 8.72% | 12.13% | -29.12% | 15.67% | 9.95% | 16.84% | -17.49% | 0.79% | -22.45% |
| 2005/12/31 | 10.66% | — | 12.54% | 9.80% | 8.05% | 21.62% | 17.94% | 10.33% | 6.88% | -22.54% | 5.25% | -37.05% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
Bristol-Myers Squibb Co.、 ROA、長期トレンド、産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
| Bristol-Myers Squibb Co. | 製薬、バイオテクノロジー、ライフサイエンス | |
|---|---|---|
| 2024/12/31 | -9.66% | 5.30% |
| 2023/12/31 | 8.43% | 7.25% |
| 2022/12/31 | 6.53% | 10.67% |
| 2021/12/31 | 6.40% | 10.42% |
| 2020/12/31 | -7.61% | 5.45% |
| 2019/12/31 | 2.65% | 9.02% |
| 2018/12/31 | 14.06% | 8.97% |
| 2017/12/31 | 3.00% | 5.28% |
| 2016/12/31 | 13.22% | 8.61% |
| 2015/12/31 | 4.93% | 8.93% |
| 2014/12/31 | 5.94% | 9.45% |
| 2013/12/31 | 6.64% | 9.46% |
| 2012/12/31 | 5.46% | 8.30% |
| 2011/12/31 | 11.25% | 7.30% |
| 2010/12/31 | 9.98% | 7.07% |
| 2009/12/31 | 34.22% | 10.02% |
| 2008/12/31 | 17.76% | 10.37% |
| 2007/12/31 | 8.27% | 8.86% |
| 2006/12/31 | 6.20% | 11.91% |
| 2005/12/31 | 10.66% | 10.42% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
業界との比較: 医療
Bristol-Myers Squibb Co.、 ROA、長期トレンド、業界との比較: 医療
| Bristol-Myers Squibb Co. | 医療 | |
|---|---|---|
| 2024/12/31 | -9.66% | 5.03% |
| 2023/12/31 | 8.43% | 6.47% |
| 2022/12/31 | 6.53% | 8.43% |
| 2021/12/31 | 6.40% | 8.29% |
| 2020/12/31 | -7.61% | 5.45% |
| 2019/12/31 | 2.65% | 7.18% |
| 2018/12/31 | 14.06% | 6.22% |
| 2017/12/31 | 3.00% | 5.24% |
| 2016/12/31 | 13.22% | 6.99% |
| 2015/12/31 | 4.93% | 7.36% |
| 2014/12/31 | 5.94% | 8.16% |
| 2013/12/31 | 6.64% | 8.27% |
| 2012/12/31 | 5.46% | 7.68% |
| 2011/12/31 | 11.25% | 6.96% |
| 2010/12/31 | 9.98% | 6.89% |
| 2009/12/31 | 34.22% | 9.13% |
| 2008/12/31 | 17.76% | 8.55% |
| 2007/12/31 | 8.27% | 8.15% |
| 2006/12/31 | 6.20% | 9.80% |
| 2005/12/31 | 10.66% | 9.10% |
レポートに基づく: 10-K (報告日: 2024-12-31), 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).